LEXICON PHARMS INC
PharmaLEXICON PHARMS INC is a pharmaceutical company focused on Cardiovascular, Metabolic. Key products include INPEFA.
LEXICON PHARMS INC at a Glance
- Strong track record with 86% execution quality across 60 trials
- Fast trial execution (21 months median completion)
LEXICON PHARMS INC's Key Drugs
LEXICON PHARMS INC's core commercial portfolio centers on INPEFA, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
LEXICON PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for LEXICON PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
LEXICON PHARMS INC's Therapeutic Areas
LEXICON PHARMS INC's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LEXICON PHARMS INC's Top Competitors
LEXICON PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LEXICON PHARMS INC Pipeline Snapshot
Active clinical trials for LEXICON PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • INPEFA leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 14/18 completed
- • Speed: 21 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-05-26
- Latest
- 2023-05-26
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges